The Pfizer and Johnson & Johnson-backed cancer treatment developer is eyeing expansion in Asia after receiving $40m in additional series D funding.
US-based oncology therapy technology developer Reflexion secured $40m on Tuesday from healthcare-focused investment firm Ally Bridge Group to expand a series D round featuring pharmaceutical firms Pfizer and Johnson & Johnson to $150m. The company said it raised $110m of series D funding across 2020, including $100m from investors including Pfizer Ventures and Johnson &…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
